Chemistry and biology of ras farnesyltransferase
- 76 Downloads
Mutated forms of ras are found in many human tumors and the rate of incidence is significantly higher in colon and pancreatic cancers. The protein product from theras oncogene is a small G-protein, p21ras(Ras) that is known to play a key role in the signal transduction cascade and cell differentiation and proliferation. Mutated Ras is unable to regulate itself and remains constantly activated, leading to uncontrolled cell growth. The function of Ras in signal transduction requires its location near the growth factor receptor at the cell membrane. However, Ras does not have a transmembrane domain. Ras requires farnesylation to increase its hydrophobicity and subsequent plasma membrane association for its transforming activity. This key post-translational modification is catalyzed by the enzyme Ras farnesyltransferase (FTase), which transfers a farnesyl group from famesylpyrophosphate to theC-terminal cysteine of the Ras protein. The requirement has focused attention on FTase as a target for therapeutic intervention. Selective inhibition of FTase will prevent Ras protein from association with the plasma membrane, leading to a disruption of oncogenic Ras function.
Key wordsras Oncogene Ras Signal transduction cascade Ras Farnesyltransferase CAAX motif Peptidomimetics
Unable to display preview. Download preview PDF.
- Bolton, G. L., Sebolt-Leopold, J. S. and Hodges, J. C., In Bristol, J. A. (Ed.),Annual reports in Medicinal Chemistry, vol. 29, Academic Press, New York, pp165–174, (1994).Google Scholar
- Brown, M. S., Goldstein, J. L., Paris, K. J., Burnier, J. P. and Marsters, J. J., Tetrapeptide inhibitors of protein farnesy-Itransferase: Amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.Proc. Natl. Acad.Sci. USA, 89, 8313–8316 (1992).PubMedCrossRefGoogle Scholar
- Cox, A. D. and Der, C. J., Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?.Biochim. Biophy. Acta., 1333, F51-F71 (1997).Google Scholar
- Hamilton, A. D. and Sebti, S. M., Inhibitors of Ras farnesyltransferase as novel antitumor agents.Drug News Perspect., 8, 138–145 (1995).Google Scholar
- Kobran, K. S., Culberson, J. C., Desolms, S. J., Giuliani, E. A., Mosser, S. D., Omer, CA., Pitzenberger, S. M. and Bogusky, M. J., NMR studies of novel inhibitors bound to farnesyl protein transferase.Protein Sci., 4, 681–688 (1995).Google Scholar
- Krengel, U., Schlichting, I., Scherer, A., Schumann, R., French, M., John, J., Kabsch, W., Pai, E. F. and Wittinghofer, A., Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules.Cell, 62, 539–548 (1990).PubMedCrossRefGoogle Scholar
- Leonard, D. M., Shuler, K. R., Poulter, C. J., Eaton, S. R., Sawyer, T. K., Hodges, J. C., Su, T.-Z., Scholten, J. D., Gowan, R. C., Sebolt-Leopold, J. S. and Doherty, A. M., Structure-activity relationships of cysteine-locking pentapeptide derivatives that inhibit ras farnesyltransferase.J. Med. Chem., 40, 192–200 (1997).PubMedCrossRefGoogle Scholar
- Masrers, J. C., Jr., McDowell, R. S., Reynilds, M. E., Oare, D. A., Somers, T. C., Stanley, M. S., Rawson, T. E., Struble, M. E., Burdick, D. J., Chan, K. S., Duarte, C. M., Paris, K. J., Tom, J. Y., Wan, D. T., Xue, Y. and Burnier, J. P., Benzodiazepine peptidomimetic inhibitors of farnesylferase.Bioorg. Med. Chem., 2, 949–957 (1994).CrossRefGoogle Scholar
- Patel, D. V., Gordon, E. M., Schmidt, R. J., Weller, H. N., Young, M. G., Zahler, R., Barbacid, M., Carboni, J. M., Gullo-Brown, J. L., Huniham, L., Ricca, C., Robinson, S., Seizinger, B. R., Tuomari, A. V. and Mann, V., Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase.J. Med. Chem., 38, 435–42 (1995).PubMedCrossRefGoogle Scholar
- Strickland, C. L., Windsor, W. T., Syto, R., Wang, L., Bond, R., Wu, Z., Schwartz, J., Le, H. V., Beese, L. S. and Weber, P. C., Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue.Biochemistry, 37, 16601–16611 (1998).PubMedCrossRefGoogle Scholar